Furthermore, GLP-1 RAs via the amelioration in insulin resistance and lipid profile [79], along with the decrease in blood pressure and body weight [80], can provide a clinically meaningful cardiovascular risk reduction. This evidence concerns the gene GLP1R and Insulin resistance.